OBR Daily Commentary

forumImage

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

(Takeda) May 22, 2020 - Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.

Read Article arrow

H. Jack West, MD (Posted: May 26, 2020)

quotesAnother option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib ended up with overall survival results that appear no better and even numerically inferior to what we've seen with alectinib. Accordingly, I don't think there's reason to expect brigatinib should displace alectinib as the prevailing favored standard of care in this setting.quotes

Add Comment 1 Comment
forumImage

Low-dose Erlotinib Effective In Frail Patients, Early Trial Suggests

(Reuters Health) May 21, 2020 - Low-dose erlotinib is safe and effective in elderly or frail patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), a new single-arm phase-2 trial suggests.

Read Article arrow

H. Jack West, MD (Posted: May 24, 2020)

quotesElderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse effects. Nice to have some prospective data on a question we've been asking and sometimes empirically managing differently based on our inferences for over a decade. quotes

Add Comment 1 Comment
forumImage

Roche’s Tecentriq Gains New First-line Lung Cancer Use

(Pharmaphorum [UK]) May 19, 2020 - Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients. Tecentriq (atezolizumab) has been approved in untreated adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high levels of the PD-L1 biomarker, with no EGFR or ALK mutations.

Read Article arrow

H. Jack West, MD (Posted: May 21, 2020)

quotesWhile it's always nice to have another option, it's hard for me to see how atezolizumab provides any advantage over pembrolizumab in what is a nearly identical clinical setting. Oncologists have been happy using pembro monotherapy for patients with tumors demonstrating high tumor PD-L1 expression (50% or greater) since late 2016, and now there is a newly approved dose and schedule for pembro every 6 weeks. I don't see any group or setting in which atezo monotherapy is a better option.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...